Preprint / Version 4

Mechanics of HTLV - 1 Driven ATL


  • Shivam Mohanty Round Rock High School



Luekemia, Cancer, HTLV - 1, Adult T-Cell Luekemia, Biology, Virus


HTLV - 1 (Human T - lymphotropic Virus -1) is a retrovirus that can cause a non-Hodgkin’s ATL (Adult T - Leukemia/ Lymphoma). This virus can develop into ATL after a latency period of 30+ years after initial infection and integration of the viral genome into the host genome. (International Agency for Research on Cancer, 2012) This disease can be hard to treat in its ``Aggressive” forms as stated by the Lymphoma Research Foundation. This virus can be spread through bodily fluids such as semen or breast milk from an infected person as described by the WHO.  Although less than 5% of people who have HTLV - 1 develop ATL, most patients with ATL pass away with a median survival rate of 8 months and a 4-year survival rate of 12%. Kensai Tobinai(2009). ATL is currently known to have 4 subtypes; Smoldering, Chronic, Acute, and Lymphomatous. Shimoyama M. (1991). They vary by their location and progression within the body. Currently, there is no vaccine against the virus, and ATL has no set treatment, guaranteeing life. David I. Marks, Clare Rowntree(2017).  The virus-driven ATL is known to have low genetic diversity across the endemic regions of southern Japan, South America, The Caribbean, and tropical Africa. Gessain and Cassar, (2012) This is interesting since ATL has been previously thought to be driven by viral proteins rather than host genetics. Bangham, C. R., & Ratner, L. (2015); Toshiki Watanabi(2017).

This suggests host-driven genetic factors that drive the development of ATL. In addition, the integration sites of the viral genome are near host cancer genetic markers.Rosewick, N., Durkin, K., Artesi, M. et al (2017) . In this review, we present the evidence gathered to date that demonstrates the correlation between patient genetics and HTLV - 1 driven ATL.



IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological Agents. Lyon (FR): International Agency for Research on Cancer; 2012. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 100B.) HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE 1. Available from:

Vahlne, A. A historical reflection on the discovery of human retroviruses. Retrovirology 6, 40 (2009).

Jégado, B., Kashanchi, F., Dutartre, H. et al. STLV-1 as a model for studying HTLV-1 infection. Retrovirology 16, 41 (2019).

Yoshiya Sato, Yoshiyuki Shiroma,Concurrent infections with Strongyloides and T-cell leukemia virus and their possible effect on immune responses of host,Clinical Immunology and Immunopathology,52, 2 1989,

Shimoyama M. (1991). Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). British journal of haematology, 79(3), 428–437.

Rosewick, N., Durkin, K., Artesi, M. et al. Cis-perturbation of cancer drivers by the HTLV-1/BLV proviruses is an early determinant of leukemogenesis. Nat Commun 8, 15264 (2017).

Alvarez, C., Gotuzzo, E., Vandamme, A. M., & Verdonck, K. (2016). Family Aggregation of Human T-Lymphotropic Virus 1-Associated Diseases: A Systematic Review. Frontiers in microbiology, 7, 1674.

Jégado, B., Kashanchi, F., Dutartre, H. et al. STLV-1 as a model for studying HTLV-1 infection. Retrovirology 16, 41 (2019).

Bangham, C. R., & Ratner, L. (2015). How does HTLV-1 cause adult T-cell leukaemia/lymphoma (ATL)?. Current opinion in virology, 14, 93–100. Nobre, A., Almeida, D. S., Ferreira, L. C., Ferreira, D. L., Júnior, E., Viana, M., Silva, I. C., Pinheiro, B. T., Ferrari, S. F., Linhares, A., Ishikawa, E. A., Sousa, R., & de Sousa, M. S. (2018). Low genetic diversity of the Human T-cell Lymphotropic Virus (HTLV-1) in an endemic area of the Brazilian Amazon basin. PloS one, 13(3), e0194184.

Jégado, B., Kashanchi, F., Dutartre, H. et al. STLV-1 as a model for studying HTLV-1 infection. Retrovirology 16, 41 (2019).

World Health Organization(WHO)

Center for Disease Control and Prevention (CDC)

Schär, F., Trostdorf, U., Giardina, F., Khieu, V., Muth, S., Marti, H., Vounatsou, P., & Odermatt, P. (2013). Strongyloides stercoralis: Global Distribution and Risk Factors. PLoS neglected tropical diseases, 7(7), e2288.



2022-10-12 — Updated on 2022-12-23